-

$undefined

N/A

(N/A)

Arcus Biosciences NEW YORK STOCK EXCHANGE INC.:RCUS Arcus Biosciences is an oncology-focused biopharmaceutical company leveraging its deep cross-disciplinary expertise to discover highly differentiated therapies and to develop a broad portfolio of novel combinations addressing significant unmet needs. Arcus currently has four molecules in clinical development: Etrumadenant (AB928), the first dual A2a/A2b adenosine receptor antagonist to enter the clinic, is being evaluated in multiple Phase 2 and 1b studies across different indications, including prostate, colorectal, non-small cell lung, pancreatic and triple-negative breast cancers. AB680, the first small-molecule CD73 inhibitor to enter the clinic, is in Phase 1/1b development for first-line treatment of metastatic pancreatic cancer in combination with zimberelimab and gemcitabine/nab-paclitaxel. Domvanalimab (AB154), an anti-TIGIT monoclonal antibody and new potential immuno-oncology backbone therapy, is in a three-arm randomized Phase 2 study for first-line treatment of PD-L1- 1.

Location: | Website: www.arcusbio.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing

Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

3.034M

Cash

1.089B

Avg Qtr Burn

-39.5M

Short % of Float

12.06%

Insider Ownership

5.59%

Institutional Own.

82.59%

Qtr Updated

09/30/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Domvanalimab (FcR-silent TIGIT antibody) Details Non-small cell lung carcinoma, Cancer	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Domvanalimab (FcR-silent TIGIT antibody) Details Cancer, Gastrointestinal stromal tumors, Gastroesophageal junction tumors, Gastroesophageal adenocarcinomas	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Casdatifan/AB521 (HIF-2a inhibitor) + cabozantinib Details Cancer, Solid tumor/s, Renal cell carcinoma	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Quemliclustat (AB680) (CD73 inhibitor) +/- zimberelimab Details Pancreatic cancer, Cancer	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Domvanalimab (FcR-silent TIGIT antibody) Details Cancer, Esophageal cancer, Gastroesophageal junction tumors, Gastric cancer	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Etrumadenant (AB928) (A2a/A2b adenosine receptor antagonist) Details Non-small cell lung carcinoma, Cancer	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Etrumadenant (AB928) + atezolizumab Details Cancer, Pancreatic cancer	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Quemliclustat (AB680) (CD73 inhibitor) + Domvanalimab + Zimberelimab Details Cancer, Non-small cell lung carcinoma	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Casdatifan/AB521 + zanzalintinib Details Cancer, Renal cell carcinoma, Solid tumor/s	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Etrumadenant (AB928) + Zimberelimab Details Colorectal cancer , Metastatic colorectal cancer, Cancer	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AB598 (anti-CD39 antibody) +/- zimberelimab + chemotherapy Details Cancer, Advanced malignancies	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Casdatifan/AB521 (HIF-2a inhibitor) Details Cancer, Solid tumor/s, Renal cell carcinoma	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AB801 (AXL inhibitor) Details Advanced malignancies, Cancer	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Etrumadenant (AB928) (A2a/A2b adenosine receptor antagonist) + Zimberelimab + docetaxel Details Cancer, Prostate cancer, Castration-resistant prostate cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.